5th Annual Cell and Gene Therapy Congress

Memo

We will welcome over 350 delegates representing leading biotechnology companies, global pharmaceutical organisations, and internationally renowned academic institutions. Over 30 presentations, case studies and panel discussions focussed on Cell and Gene Therapy development and clinical research, the commercialisation of CAR T treatments, and Cell and Gene Therapy bioprocessing and manufacturing strategies. 3 interactive streams: Day 1 Stream 1: Cell and Gene Therapy Development and Clinical TrialsDay 1 Stream 2: Cell and Gene Therapy Bioprocessing and Manufacturing StrategiesDay 2 Stream 1: Commercialising Cell and Gene Therapy Treatments14 pre-scheduled one to one meetings, exhibition and informal networking opportunities. Co-located with our highly anticipated 8th Annual Cell Culture and Bioprocessing Congress, 6th Annual Stem Cell and Regenerative Medicine Congress and 2nd Annual Biobanking Congress. URLs:Tickets: https://go.evvnt.com/395618-2?pid=5569Brochure: https://go.evvnt.com/395618-3?pid=5569 On Tuesday October 29, 2019 at 7:30 am (ends Wednesday October 30, 2019 at 6:00 pm) Price:Registration Available from: GBP 299.0 Speakers: Axel Hoos, Senior Vice President and Oncology Therapeutic Area Head, GlaxoSmithKline, Peter Olagunju, Vice President, Patient Operations and Lentiglobin Program Leader, bluebird bio, David Gilham, Vice President, Research and Development, Celyad, Paul Lammers, President and Chief Executive Officer, Triumvira Therapeutics, Soraya Bekkali, Chief Executive Officer, Gyroscope Therapeutics Venue Details: Hotel Novotel London West, Hammersmith International Ctre 1, Shortlands, London, W6 8DR, United Kingdom